Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial
Gordon Fernie (Corresponding Author), James Currie, Jennifer S. Perrin, Caroline A. Stewart, Virginica Anderson, Daniel M. Bennett, Steven Hay, Ian C. Reid
Applied Health Sciences
Ketamine has recently become an agent of interest as an acute treatment for severe depression and as the anaesthetic for electroconvulsive therapy (ECT). Subanaesthetic doses result in an acute reduction in depression severity while evidence is equivocal for this antidepressant effect with anaesthetic or adjuvant doses. Recent systematic reviews call for high-quality evidence from further randomised controlled trials (RCTs).
To establish if ketamine as the anaesthetic for ECT results in fewer ECT treatments, improvements in depression severity ratings and less memory impairment than the standard anaesthetic.
Double-blind, parallel-design, RCT of intravenous ketamine (up to 2 mg/kg) with an active comparator, intravenous propofol (up to 2.5 mg/kg), as the anaesthetic for ECT in patients receiving ECT for major depression on an informal basis. (Trial registration: European Clinical Trials Database (EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)
No significant differences were found on any outcome measure during, at the end of or 1 month following the ECT course.
Ketamine as an anaesthetic does not enhance the efficacy of ECT.
British Journal of Psychiatry
https://doi.org/10.1192/bjp.bp.116.189134
10.1192/bjp.bp.116.189134Licence: CC BY-NC-ND
This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) licence. https://creativecommons.org/licenses/by-nc-nd/4.0/
Final published version, 605 KBLicence: CC BY-NC-ND
Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial – CORRIGENDUM
Fingerprint Dive into the research topics of 'Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial'. Together they form a unique fingerprint.
Electroconvulsive Therapy Medicine & Life Sciences
Ketamine Medicine & Life Sciences
Anesthetics Medicine & Life Sciences
Anesthesia Adjuvants Medicine & Life Sciences
Propofol Medicine & Life Sciences
Antidepressive Agents Medicine & Life Sciences
Fernie, G., Currie, J., Perrin, J. S., Stewart, C. A., Anderson, V., Bennett, D. M., Hay, S., & Reid, I. C. (2017). Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial. British Journal of Psychiatry, 210(3), 1-7. https://doi.org/10.1192/bjp.bp.116.189134
Ketamine as the anaesthetic for electroconvulsive therapy : the KANECT randomised controlled trial. / Fernie, Gordon (Corresponding Author); Currie, James; Perrin, Jennifer S.; Stewart, Caroline A. ; Anderson, Virginica; Bennett, Daniel M.; Hay, Steven; Reid, Ian C.
In: British Journal of Psychiatry, Vol. 210, No. 3, 06.2017, p. 1-7.
Fernie, G, Currie, J, Perrin, JS, Stewart, CA, Anderson, V, Bennett, DM, Hay, S & Reid, IC 2017, 'Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial', British Journal of Psychiatry, vol. 210, no. 3, pp. 1-7. https://doi.org/10.1192/bjp.bp.116.189134
Fernie G, Currie J, Perrin JS, Stewart CA, Anderson V, Bennett DM et al. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial. British Journal of Psychiatry. 2017 Jun;210(3):1-7. https://doi.org/10.1192/bjp.bp.116.189134
Fernie, Gordon ; Currie, James ; Perrin, Jennifer S. ; Stewart, Caroline A. ; Anderson, Virginica ; Bennett, Daniel M. ; Hay, Steven ; Reid, Ian C. / Ketamine as the anaesthetic for electroconvulsive therapy : the KANECT randomised controlled trial. In: British Journal of Psychiatry. 2017 ; Vol. 210, No. 3. pp. 1-7.
@article{1402da20346449678e43db463a57afd2,
title = "Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial",
abstract = "BackgroundKetamine has recently become an agent of interest as an acute treatment for severe depression and as the anaesthetic for electroconvulsive therapy (ECT). Subanaesthetic doses result in an acute reduction in depression severity while evidence is equivocal for this antidepressant effect with anaesthetic or adjuvant doses. Recent systematic reviews call for high-quality evidence from further randomised controlled trials (RCTs).AimsTo establish if ketamine as the anaesthetic for ECT results in fewer ECT treatments, improvements in depression severity ratings and less memory impairment than the standard anaesthetic.MethodDouble-blind, parallel-design, RCT of intravenous ketamine (up to 2 mg/kg) with an active comparator, intravenous propofol (up to 2.5 mg/kg), as the anaesthetic for ECT in patients receiving ECT for major depression on an informal basis. (Trial registration: European Clinical Trials Database (EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)ResultsNo significant differences were found on any outcome measure during, at the end of or 1 month following the ECT course.ConclusionsKetamine as an anaesthetic does not enhance the efficacy of ECT.",
author = "Gordon Fernie and James Currie and Perrin, {Jennifer S.} and Stewart, {Caroline A.} and Virginica Anderson and Bennett, {Daniel M.} and Steven Hay and Reid, {Ian C.}",
note = "C.AS. reports grants from Vifor Pharma, outside the submitted work. I.C.R. (deceased) declared personal fees from AstraZeneca, Sanofi Aventis and Sunovion, and non-financial support from Lundbeck, between 2009 and 2014 and all outside the submitted work. Volume 212, Issue 5 May 2018 , p. 323 Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial – CORRIGENDUM Gordon Fernie, James Currie, Jennifer S. Perrin, Caroline A. Stewart... https://doi.org/10.1192/bjp.2018.76 Published online: 06 April 2018 Summary: This notice describes a correction to the above mentioned paper. ",
doi = "10.1192/bjp.bp.116.189134",
journal = "British Journal of Psychiatry",
publisher = "Royal College of Psychiatrists",
T1 - Ketamine as the anaesthetic for electroconvulsive therapy
T2 - the KANECT randomised controlled trial
AU - Fernie, Gordon
AU - Currie, James
AU - Perrin, Jennifer S.
AU - Stewart, Caroline A.
AU - Anderson, Virginica
AU - Bennett, Daniel M.
AU - Hay, Steven
AU - Reid, Ian C.
N1 - C.AS. reports grants from Vifor Pharma, outside the submitted work. I.C.R. (deceased) declared personal fees from AstraZeneca, Sanofi Aventis and Sunovion, and non-financial support from Lundbeck, between 2009 and 2014 and all outside the submitted work. Volume 212, Issue 5 May 2018 , p. 323 Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial – CORRIGENDUM Gordon Fernie, James Currie, Jennifer S. Perrin, Caroline A. Stewart... https://doi.org/10.1192/bjp.2018.76 Published online: 06 April 2018 Summary: This notice describes a correction to the above mentioned paper.
N2 - BackgroundKetamine has recently become an agent of interest as an acute treatment for severe depression and as the anaesthetic for electroconvulsive therapy (ECT). Subanaesthetic doses result in an acute reduction in depression severity while evidence is equivocal for this antidepressant effect with anaesthetic or adjuvant doses. Recent systematic reviews call for high-quality evidence from further randomised controlled trials (RCTs).AimsTo establish if ketamine as the anaesthetic for ECT results in fewer ECT treatments, improvements in depression severity ratings and less memory impairment than the standard anaesthetic.MethodDouble-blind, parallel-design, RCT of intravenous ketamine (up to 2 mg/kg) with an active comparator, intravenous propofol (up to 2.5 mg/kg), as the anaesthetic for ECT in patients receiving ECT for major depression on an informal basis. (Trial registration: European Clinical Trials Database (EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)ResultsNo significant differences were found on any outcome measure during, at the end of or 1 month following the ECT course.ConclusionsKetamine as an anaesthetic does not enhance the efficacy of ECT.
AB - BackgroundKetamine has recently become an agent of interest as an acute treatment for severe depression and as the anaesthetic for electroconvulsive therapy (ECT). Subanaesthetic doses result in an acute reduction in depression severity while evidence is equivocal for this antidepressant effect with anaesthetic or adjuvant doses. Recent systematic reviews call for high-quality evidence from further randomised controlled trials (RCTs).AimsTo establish if ketamine as the anaesthetic for ECT results in fewer ECT treatments, improvements in depression severity ratings and less memory impairment than the standard anaesthetic.MethodDouble-blind, parallel-design, RCT of intravenous ketamine (up to 2 mg/kg) with an active comparator, intravenous propofol (up to 2.5 mg/kg), as the anaesthetic for ECT in patients receiving ECT for major depression on an informal basis. (Trial registration: European Clinical Trials Database (EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)ResultsNo significant differences were found on any outcome measure during, at the end of or 1 month following the ECT course.ConclusionsKetamine as an anaesthetic does not enhance the efficacy of ECT.
UR - http://10.1192/bjp.2018.76
U2 - 10.1192/bjp.bp.116.189134
DO - 10.1192/bjp.bp.116.189134
JO - British Journal of Psychiatry
JF - British Journal of Psychiatry